2. Search Result
Search Result
Pathways Recommended: Cell Cycle/DNA Damage
Results for "

bacterial DNA topoisomerase II

" in MedChemExpress (MCE) Product Catalog:

25

Inhibitors & Agonists

1

Fluorescent Dyes

2

Biochemical Assay Reagents

1

Natural
Products

3

Isotope-Labeled Compounds

1

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0330D
    (R)-Ofloxacin
    1 Publications Verification

    Dextrofloxacin

    		 Bacterial Antibiotic Infection
    (R)-Ofloxacin is the dextrorotatory enantiomer of Ofloxacin (HY-B0125) and is an orally effective fluoroquinolone antibiotic. (R)-Ofloxacin can inhibit the activity of bacterial DNA topoisomerase II, interfere with bacterial DNA replication and repair, and exert a bactericidal effect. (R)-Ofloxacin has a broad-spectrum antibacterial activity and has inhibitory effects on both Gram-negative and Gram-positive bacteria .
    (R)-Ofloxacin
  • HY-10581
    Gatifloxacin
    4 Publications Verification

    AM-1155; BMS-206584; PD135432

    		 Bacterial Topoisomerase Antibiotic Infection Neurological Disease Cancer
    Gatifloxacin (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic that can cross the blood-brain barrier, with broad-spectrum antibacterial activity. Gatifloxacin inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50=0.109 μg/ml) . Gatifloxacin can be used to treat bacterial conjunctivitis in vivo.
    Gatifloxacin
  • HY-B0455
    Lomefloxacin hydrochloride

    SC47111A hydrochloride; NY-198 hydrochloride

    		 Antibiotic Bacterial Topoisomerase Reactive Oxygen Species (ROS) Apoptosis Infection Endocrinology Cancer
    Lomefloxacin hydrochloride (NY-198 hydrochloride) is an orally active difluoroquinolone antibiotic. Lomefloxacin hydrochloride prevents DNA supercoiling and replication by inhibiting bacterial topoisomerase II. Lomefloxacin hydrochloride induces ROS production and Apoptosis. Lomefloxacin hydrochloride has broad-spectrum bactericidal activity against Gram-positive and Gram-negative bacteria. Lomefloxacin hydrochloride has anticancer effects against melanoma. Lomefloxacin hydrochloride can be used in the study of systemic bacterial infections (such as Salmonella typhimurium infections), skin and melanoma .
    Lomefloxacin hydrochloride
  • HY-N7066
    Difloxacin hydrochloride

    A-56619 hydrochloride

    		 Bacterial DNA/RNA Synthesis Infection
    Difloxacin hydrochloride (A-56619 hydrochloride) is an orally active bactericidal agent. Difloxacin hydrochloride inhibits bacterial DNA gyrase. Difloxacin hydrochloride exhibits concentration-dependent bactericidal activity. Difloxacin hydrochloride shows strong in vitro activity against a variety of Gram-positive and Gram-negative bacteria. Difloxacin hydrochloride can be used in research related to colibacillosis and *Staphylococcus aureus* infections .
    Difloxacin hydrochloride
  • HY-10581A
    Gatifloxacin hydrochloride
    4 Publications Verification

    AM-1155 hydrochloride; BMS-206584 hydrochloride; PD135432 hydrochloride

    		 Bacterial Topoisomerase Antibiotic Infection
    Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml) . Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.
    Gatifloxacin hydrochloride
  • HY-B0455A
    Lomefloxacin

    SC47111A; NY-198

    		 Bacterial Antibiotic Topoisomerase Reactive Oxygen Species (ROS) Apoptosis Infection
    Lomefloxacin (SC47111A) is an orally active difluoroquinolone antibiotic. Lomefloxacin prevents DNA supercoiling and replication by inhibiting bacterial topoisomerase II. Lomefloxacin induces ROS production and Apoptosis. Lomefloxacin has broad-spectrum bactericidal activity against Gram-positive and Gram-negative bacteria. Lomefloxacin has anticancer effects against melanoma. Lomefloxacin can be used in the study of systemic bacterial infections (such as Salmonella typhimurium infections), skin and melanoma .
    Lomefloxacin
  • HY-16742B
    Gepotidacin mesylate hydrate
    Maximum Cited Publications
    12 Publications Verification

    		 Antibiotic Bacterial Topoisomerase Infection
    Gepotidacin mesylate hydrate is an orally active triazaacenaphthylene antibiotic and bacterial type II topoisomerase inhibitor. Gepotidacin mesylate hydrate inhibits bacterial DNA replication by blocking topoisomerase enzymes. Gepotidacin mesylate hydrate selectively inhibits topoisomerase IV and the B subunit of DNA gyrase .
    Gepotidacin mesylate hydrate
  • HY-10581C
    Gatifloxacin sesquihydrate

    AM-1155 sesquihydrate; BMS-206584 sesquihydrate; PD135432 sesquihydrate

    		 Bacterial Topoisomerase Antibiotic Infection Inflammation/Immunology
    Gatifloxacin sesquihydrate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin sesquihydrate inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml) . Gatifloxacin sesquihydrate can be used to treat bacterial conjunctivitis in vivo.
    Gatifloxacin sesquihydrate
  • HY-172229
    NBTI 5463

    		Topoisomerase Bacterial Infection
    NBTI 5463 is a bacterial type II topoisomerases (topoisomerase II) inhibitor with antibacterial activity. NBTI 5463 inhibits GyrA and TopoIV in Pseudomonas aeruginosa and Escherichia coli. NBTI 5463 binds to topoisomerase II to prevent DNA cleavage and religation, inhibiting bacterial DNA replication and transcription. NBTI 5463 is promising for research of Gram-negative bacterial infection .
    NBTI 5463
  • HY-117657
    (-)-BO 2367

    		Topoisomerase Bacterial Inflammation/Immunology Cancer
    (-)-BO 2367, an antimicrobial quinolone, is a strong mammalian and bacterial topoisomerase II inhibitor. (-)-BO 2367 shows IC50 values with 3.8 μM, 0.5 μM, and 1 μM against the DNA relaxation activity of L1210 topoisomerase II and the supercoiling activities of Escherichia coli gyrase and Micrococcus luteus gyrase, respectively. (-)-BO 2367 is a potent antitumor agent .
    (-)-BO 2367
  • HY-10581B
    Gatifloxacin mesylate

    AM-1155 mesylate; BMS-206584 mesylate; PD135432 mesylate

    		 Bacterial Topoisomerase Antibiotic Infection
    Gatifloxacin mesylate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin mesylate inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml) . Gatifloxacin mesylate can be used to treat bacterial conjunctivitis in vivo.
    Gatifloxacin mesylate
  • HY-173192
    Antibacterial agent 272

    		Bacterial Infection
    Antibacterial agent 272 (Compound Z22) is a potential antimicrobial agent targeting DNA and the DNA-topoisomerase II (DNA-Topo II) complex, exhibiting MIC values of 1 μg/mL against Staphylococcus aureus 25923 and 29213, 2 μg/mL against Staphylococcus epidermidis 12228, 2-4 μg/mL against Enterococcus faecalis, and 4 μg/mL against Pseudomonas aeruginosa 9027 and 27853, demonstrating potent antibacterial activity. This compound functions by intercalating with DNA base pairs to disrupt normal bacterial DNA function, making it suitable for research on bacterial infectious diseases .
    Antibacterial agent 272
  • HY-10581AS
    Gatifloxacin-d3 hydrochloride

    AM-1155-d3 hydrochloride; BMS-206584-d3 hydrochloride; PD135432-d3 hydrochloride

    		 Isotope-Labeled Compounds Bacterial Topoisomerase Antibiotic Infection
    Gatifloxacin-d3 (hydrochloride) is the deuterium labeled Gatifloxacin (hydrochloride). Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml). Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.
    Gatifloxacin-d3 hydrochloride
  • HY-10581AR
    Gatifloxacin hydrochloride (Standard)

    AM-1155 hydrochloride (Standard); BMS-206584 hydrochloride (Standard); PD135432 hydrochloride (Standard)

    		 Reference Standards Bacterial Topoisomerase Antibiotic Infection
    Gatifloxacin (hydrochloride) (Standard) is the analytical standard of Gatifloxacin (hydrochloride). This product is intended for research and analytical applications. Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml)[1]. Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.
    Gatifloxacin hydrochloride (Standard)
  • HY-W700069
    Gatifloxacin-d4

    AM-1155-d4; BMS-206584-d4; PD135432-d4

    		 Isotope-Labeled Compounds Antibiotic Bacterial Topoisomerase Infection
    Gatifloxacin-d4 (AM-1155-d4) is the deuterium labeled Gatifloxacin (HY-10581). Gatifloxacin (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin inhibits bacterial type II topoisomerases (IC50 = 13.8 μg/mL for S. aureus topoisomerase IV) and E.coli DNA gyrase (IC50 = 0.109 μg/mL) . Gatifloxacin can be used for the study of bacterial conjunctivitis in vivo.
    Gatifloxacin-d4
  • HY-10581R
    Gatifloxacin (Standard)

    AM-1155 (Standard); BMS-206584 (Standard); PD135432 (Standard)

    		 Reference Standards Bacterial Topoisomerase Antibiotic Infection
    Gatifloxacin (Standard) is the analytical standard of Gatifloxacin. This product is intended for research and analytical applications. Gatifloxacin (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50=0.109 μg/ml) . Gatifloxacin can be used to treat bacterial conjunctivitis in vivo.
    Gatifloxacin (Standard)
  • HY-10581CR
    Gatifloxacin sesquihydrate (Standard)

    AM-1155 sesquihydrate (Standard); BMS-206584 sesquihydrate (Standard); PD135432 sesquihydrate (Standard)

    		 Reference Standards Bacterial Topoisomerase Antibiotic Infection Inflammation/Immunology
    Gatifloxacin (sesquihydrate) (Standard) is the analytical standard of Gatifloxacin (sesquihydrate). This product is intended for research and analytical applications. Gatifloxacin sesquihydrate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin sesquihydrate inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml) . Gatifloxacin sesquihydrate can be used to treat bacterial conjunctivitis?in vivo.
    Gatifloxacin sesquihydrate (Standard)
  • HY-B0330DS
    (R)-Ofloxacin-d3

    		Isotope-Labeled Compounds Bacterial Antibiotic Infection
    (R)-Ofloxacin-d3 is the deuterium labeled (R)-Ofloxacin. (R)-Ofloxacin is the dextrorotatory enantiomer of Ofloxacin (HY-B0125) and is an orally effective fluoroquinolone antibiotic. (R)-Ofloxacin can inhibit the activity of bacterial DNA topoisomerase II, interfere with bacterial DNA replication and repair, and exert a bactericidal effect. (R)-Ofloxacin has a broad-spectrum antibacterial activity and has inhibitory effects on both Gram-negative and Gram-positive bacteria .
    (R)-Ofloxacin-d3
  • HY-B0330DR
    (R)-Ofloxacin (Standard)

    Dextrofloxacin (Standard)

    		 Reference Standards Bacterial Antibiotic Infection
    (R)-Ofloxacin (Standard) is the analytical standard of (R)-Ofloxacin (HY-B0330D). (R)-Ofloxacin is the dextrorotatory enantiomer of Ofloxacin (HY-B0125) and is an orally effective fluoroquinolone antibiotic. (R)-Ofloxacin can inhibit the activity of bacterial DNA topoisomerase II, interfere with bacterial DNA replication and repair, and exert a bactericidal effect. (R)-Ofloxacin has a broad-spectrum antibacterial activity and has inhibitory effects on both Gram-negative and Gram-positive bacteria .
    (R)-Ofloxacin (Standard)
  • HY-150045
    TP0480066

    		Topoisomerase Bacterial Infection
    TP0480066 is a selective topoisomerase II inhibitor with IC50s of 1.10 and 62.89 nM for DNA gyrase and topo IV, respectively. TP0480066 shows good activity of againsting various bacterial species including drug-resistant strains. TP0480066 also exhibits potent inhibitory activity to N. gonorrhoeae, can be used in study of gonorrhea .
    TP0480066
  • HY-W353258R
    Moxifloxacin hydrochloride monohydrate (Standard)

    BAY 12-8039 monohydrate (Standard)

    		 Reference Standards Antibiotic Topoisomerase Bacterial Infection
    Moxifloxacin hydrochloride (BAY 12-8039) monohydrate (Standard) is the analytical standard of Moxifloxacin hydrochloride monohydrate. This product is intended for research and analytical applications. Moxifloxacin hydrochloride monohydrate is a blood-brain barrier-permeable, orally active topoisomerase II/IV inhibitor and a fluoroquinolone antibiotic. Moxifloxacin hydrochloride monohydrate disrupts bacterial DNA replication, transcription, repair and chromosome segregation processes. Moxifloxacin hydrochloride monohydrate exhibits activity against Gram-positive bacteria, Gram-negative bacteria, anaerobes, atypical pathogens, drug-resistant respiratory pathogens, Mycobacterium tuberculosis, mycoplasmas and Ureaplasma urealyticum.
    Moxifloxacin hydrochloride monohydrate (Standard)
  • HY-B0455R
    Lomefloxacin hydrochloride (Standard)

    SC47111A hydrochloride (Standard); NY-198 hydrochloride (Standard)

    		 Reference Standards Bacterial Antibiotic Topoisomerase Reactive Oxygen Species (ROS) Apoptosis Infection Endocrinology Cancer
    Lomefloxacin (hydrochloride) (Standard) is the analytical standard of Lomefloxacin hydrochloride (HY-B0455). This product is intended for research and analytical applications. Lomefloxacin hydrochloride (NY-198 hydrochloride) is an orally active difluoroquinolone antibiotic. Lomefloxacin hydrochloride prevents DNA supercoiling and replication by inhibiting bacterial topoisomerase II. Lomefloxacin hydrochloride induces ROS production and Apoptosis. Lomefloxacin hydrochloride has broad-spectrum bactericidal activity against Gram-positive and Gram-negative bacteria. Lomefloxacin hydrochloride has anticancer effects against melanoma. Lomefloxacin hydrochloride can be used in the study of systemic bacterial infections (such as Salmonella typhimurium infections), skin and melanoma .
    Lomefloxacin hydrochloride (Standard)
  • HY-178738
    GC-072

    		Antibiotic Bacterial Topoisomerase DNA/RNA Synthesis Infection
    GC-072 is an orally active, 4-oxoquinolizine antibiotic that selectively inhibits bacterial DNA gyrase and Topo IV enzymes. GC-072 does not inhibit human topoisomerases I and II. GC-072 demonstrates strong antimicrobial activity against various bacterial strains, including Gram-positive, Gram-negative, and resistant bacteria. GC-072 also exhibits bactericidal activity against Burkholderia pseudomallei both extracellularly and intracellularly, leading to dose-dependent survival in mice exposed to lethal inhalational models of B. pseudomallei infection. GC-072 can be used for the research of melioidosis .
    GC-072
  • HY-B0356G
    Ciprofloxacin

    Bay-09867

    		 Bacterial Topoisomerase Akt β-catenin Inflammation/Immunology
    Ciprofloxacin GMP is Ciprofloxacin (HY-B0356) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Ciprofloxacin (Bay-09867) is an orally active, blood-brain barrier permeable fluoroquinolone antibacterial agent. Ciprofloxacin exerts bactericidal effects primarily by inhibiting topoisomerase II and IV. Ciprofloxacin inhibits the proliferation of human dental pulp stem cells and chondrocytes from young rats, and also activates the Akt signaling pathway and upregulates markers such as β-catenin and Nanog to maintain the morphological characteristics of stem cells. Ciprofloxacin induces significant neurotoxicity and tissue damage, including reducing serotonin and glutathione levels in the brain, inducing oxidative stress and depression-like behaviors, and causing articular cartilage damage. Ciprofloxacin can be applied to research related to infections of necrotic young permanent teeth and neurotoxicity .
    Ciprofloxacin
  • HY-W800535
    Cryptolepine

    		NF-κB p38 MAPK mTOR Topoisomerase AMPK Apoptosis Cholinesterase (ChE) HIF/HIF Prolyl-Hydroxylase β-catenin Infection Metabolic Disease Inflammation/Immunology Cancer
    Cryptolepine is an orally active multi-potent alkaloid with anti-cancer, anti-bacterial, anti-viral, anti-malarial, anti-inflammatory, anti-hyperglycemic, relieve pain and other properties. Cryptolepine acts as an inhibitor of c-Myc, mTOR, NF-κB, HIF-1, MAPK and an activator of AMPKα1/2. It intercalates into DNA, inhibits topoisomerase II (Top II), disrupts mitochondrial dynamics and induces apoptosis. Cryptolepine also exhibits anti-plasmodial and cholinesterase inhibitory activities. Cryptolepine can be used in research related to tumors (melanoma, hepatocellular carcinoma, mammary adenocarcinoma, etc.), malaria, inflammatory diseases and diabetes, particularly in studies focused on inhibiting tumor growth and anti-plasmodial infection .
    Cryptolepine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: